<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2051">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623050</url>
  </required_header>
  <id_info>
    <org_study_id>SNS-005</org_study_id>
    <nct_id>NCT01623050</nct_id>
  </id_info>
  <brief_title>Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium</brief_title>
  <official_title>SinuSys Patency of Maxillary Sinus Ostia Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SinuSys Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SinuSys Corporation</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and performance of the SinuSys Dilation System
      for dilation of the maxillary sinus ostium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, single-arm, prospective study conducted to assess the safety and
      effectiveness of a new osmotically-driven, low-pressure expansion device for dilation of
      maxillary sinus ostia in patients with (CRS) Chronic Rhinosinusitis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patency of Treated Area</measure>
    <time_frame>Immediately post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patency of Treated Area</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maxillary Sinus Ostia Patency of 33 patients analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Device-related Adverse Events as a Measure of Safety</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency of Treated Area</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maxillary Sinus Ostia Patency of 29 patients analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency of Treated Area</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maxillary Sinus Ostia of 27 patients analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>SinuSys Dilation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maxillary Sinus Dilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SinuSys Dilation System</intervention_name>
    <description>Sinuplasty</description>
    <arm_group_label>SinuSys Dilation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Diagnosis of chronic maxillary sinusitis

        Exclusion Criteria:

          -  Previous antrostomy

          -  Sinonasal tumours

          -  Cystic fibrosis

          -  History of facial trauma that distorts sinus anatomy and precludes access to the
             maxillary sinus

          -  Pregnant or breastfeeding females

          -  Currently participating in another drug or device study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Catalano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Elizabeth Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amin Javer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley ENT</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, ENT Department</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 30, 2014</lastchanged_date>
  <firstreceived_date>June 13, 2012</firstreceived_date>
  <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SinuSys Dilation System</title>
          <description>Maxillary Sinus Dilation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>36 patients were enrolled; 2 patients withdrew consent prior to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>SinuSys Dilation System</title>
          <description>Maxillary Sinus Dilation
SinuSys Dilation System: Sinuplasty</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.1" spread="16.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patency of Treated Area</title>
        <time_frame>Immediately post procedure</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of osita treated</population>
        <group_list>
          <group group_id="O1">
            <title>SinuSys Dilation System</title>
            <description>Maxillary Sinus Dilation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Ostia analyzed</title>
            <units>Ostia</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patency of Treated Area</title>
            <units>percentage of ostia treated</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency of Treated Area</title>
        <description>Maxillary Sinus Ostia Patency of 33 patients analyzed.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>One patient was lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>SinuSys Dilation System</title>
            <description>Maxillary Sinus Dilation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Ostia analyzed</title>
            <units>Ostia</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patency of Treated Area</title>
            <description>Maxillary Sinus Ostia Patency of 33 patients analyzed.</description>
            <units>percentage of ostia patent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Device-related Adverse Events as a Measure of Safety</title>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>SinuSys Dilation System</title>
            <description>Maxillary Sinus Dilation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Device-related Adverse Events as a Measure of Safety</title>
            <units>number of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency of Treated Area</title>
        <description>Maxillary Sinus Ostia Patency of 29 patients analyzed.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>5 patients were lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>SinuSys Dilation System</title>
            <description>Maxillary Sinus Dilation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Ostia analyzed</title>
            <units>Ostia</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patency of Treated Area</title>
            <description>Maxillary Sinus Ostia Patency of 29 patients analyzed.</description>
            <units>percentage of ostia patent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency of Treated Area</title>
        <description>Maxillary Sinus Ostia of 27 patients analyzed.</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>7 patients were lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>SinuSys Dilation System</title>
            <description>Maxillary Sinus Dilation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Ostia analyzed</title>
            <units>Ostia</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patency of Treated Area</title>
            <description>Maxillary Sinus Ostia of 27 patients analyzed.</description>
            <units>percentage of ostia patent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only device related adverse events collected</desc>
      <group_list>
        <group group_id="E1">
          <title>SinuSys Dilation System</title>
          <description>Maxillary Sinus Dilation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janie Mandrusov, Director of Pre-Clinical and Clinical Development</name_or_title>
      <organization>SinuSys Corporation</organization>
      <phone>4084104411</phone>
      <email>emandrusov@sinusys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
